Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment.
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical Company
- 29 Sep 2017 Results (n=1129, data cut off 20 November 2015) published in the Annals of Oncology
- 11 Oct 2016 Primary endpoint (Overall Survival (OS)) has been met according to the results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History